Theravance Biopharma, Inc. (TBPH) Forms $29.26 Double Bottom; Orbimed Advisors Boosted Integra Lifesciences Hldgs C (IART) Position

February 17, 2018 - By John Hoffman

Theravance Biopharma, Inc. (TBPH) formed double bottom with $26.92 target or 8.00% below today’s $29.26 share price. Theravance Biopharma, Inc. (TBPH) has $1.58B valuation. The stock decreased 1.18% or $0.35 during the last trading session, reaching $29.26. About 86,699 shares traded. Theravance Biopharma, Inc. (NASDAQ:TBPH) has risen 89.85% since February 17, 2017 and is uptrending. It has outperformed by 73.15% the S&P500.

Orbimed Advisors Llc increased Integra Lifesciences Hldgs C (IART) stake by 155.54% reported in 2017Q3 SEC filing. Orbimed Advisors Llc acquired 664,000 shares as Integra Lifesciences Hldgs C (IART)’s stock rose 7.31%. The Orbimed Advisors Llc holds 1.09 million shares with $55.07 million value, up from 426,910 last quarter. Integra Lifesciences Hldgs C now has $4.10 billion valuation. The stock increased 1.61% or $0.83 during the last trading session, reaching $52.26. About 790,644 shares traded or 67.96% up from the average. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since February 17, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Orbimed Advisors Llc decreased Unitedhealth Group Inc (NYSE:UNH) stake by 48,600 shares to 380,000 valued at $74.42M in 2017Q3. It also reduced Shire Plc (NASDAQ:SHPG) stake by 148,900 shares and now owns 399,908 shares. Incyte Corp (NASDAQ:INCY) was reduced too.

Investors sentiment increased to 1.29 in Q3 2017. Its up 0.15, from 1.14 in 2017Q2. It is positive, as 22 investors sold IART shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported. Orbimed Advisors Ltd Limited Liability Company has 0.53% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Falcon Point, a California-based fund reported 255,207 shares. State Of Wisconsin Inv Board owns 278,100 shares for 0.04% of their portfolio. Swiss Bancshares, a Switzerland-based fund reported 99,994 shares. Illinois-based Segall Bryant & Hamill Limited Liability Corporation has invested 0.13% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Teachers Retirement System Of The State Of Kentucky reported 35,366 shares or 0.02% of all its holdings. Fmr Lc holds 10.33M shares or 0.06% of its portfolio. Qs Ltd Liability invested in 1,308 shares. Northwest Invest Counselors Limited Liability Company invested in 0.17% or 7,730 shares. Pinebridge Invests Lp holds 0.03% or 24,954 shares. Citigroup Inc invested in 11,585 shares. Numeric accumulated 9,300 shares. Sectoral Asset Management holds 0.92% in Integra LifeSciences Holdings Corporation (NASDAQ:IART) or 140,778 shares. Pnc Financial Group reported 0% stake.

Among 15 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Integra Lifesciences Holdings Corp. had 35 analyst reports since July 29, 2015 according to SRatingsIntel. Oppenheimer maintained the stock with “Buy” rating in Friday, June 23 report. The rating was downgraded by Bank of America on Tuesday, January 2 to “Neutral”. JMP Securities upgraded Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Friday, January 6 to “Mkt Outperform” rating. Barclays Capital maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) on Friday, July 29 with “Equal Weight” rating. JP Morgan initiated the stock with “Overweight” rating in Wednesday, July 13 report. UBS maintained the shares of IART in report on Wednesday, June 7 with “Buy” rating. Oppenheimer maintained the shares of IART in report on Wednesday, July 26 with “Buy” rating. The rating was maintained by Lake Street with “Hold” on Wednesday, August 26. The company was downgraded on Friday, October 27 by J.P. Morgan. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 9.

Among 8 analysts covering Theravance Biopharma (NASDAQ:TBPH), 7 have Buy rating, 1 Sell and 0 Hold. Therefore 88% are positive. Theravance Biopharma had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Theravance Biopharma, Inc. (NASDAQ:TBPH) earned “Buy” rating by Cantor Fitzgerald on Wednesday, August 16. The stock has “Underperform” rating by Robert W. Baird on Wednesday, October 12. The rating was maintained by Needham with “Buy” on Wednesday, August 2. The firm has “Sell” rating given on Monday, September 18 by Robert W. Baird. Evercore initiated Theravance Biopharma, Inc. (NASDAQ:TBPH) on Monday, August 29 with “Buy” rating. The rating was maintained by Cantor Fitzgerald on Wednesday, July 19 with “Buy”. The firm has “Buy” rating by Needham given on Friday, September 15. The company was maintained on Thursday, February 8 by Leerink Swann. The rating was initiated by Needham with “Buy” on Wednesday, December 21. Robert W. Baird maintained the shares of TBPH in report on Monday, October 30 with “Sell” rating.

Analysts await Theravance Biopharma, Inc. (NASDAQ:TBPH) to report earnings on February, 26. They expect $-1.15 EPS, up 15.44% or $0.21 from last year’s $-1.36 per share. After $-1.27 actual EPS reported by Theravance Biopharma, Inc. for the previous quarter, Wall Street now forecasts -9.45% EPS growth.

Investors sentiment decreased to 1.32 in Q3 2017. Its down 0.46, from 1.78 in 2017Q2. It turned negative, as 13 investors sold Theravance Biopharma, Inc. shares while 18 reduced holdings. 7 funds opened positions while 34 raised stakes. 35.46 million shares or 3.52% more from 34.25 million shares in 2017Q2 were reported. Citigroup has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). New York-based First Manhattan has invested 0.32% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Nj State Employees Deferred Compensation Plan owns 24,142 shares. Schwab Charles Investment Mngmt Incorporated holds 0.01% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 191,558 shares. Cormorant Asset Mgmt Ltd holds 5.74% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 950,000 shares. Goldman Sachs Group Inc holds 0% or 256,808 shares. Foundation Asset Mgmt Lp holds 4.61% or 432,532 shares in its portfolio. Ny State Common Retirement Fund has invested 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). State Street Corp owns 913,836 shares or 0% of their US portfolio. Qs holds 0% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 2,500 shares. Sg Americas Limited Liability Corporation, a New York-based fund reported 9,061 shares. California State Teachers Retirement reported 66,851 shares or 0.01% of all its holdings. Moreover, Barclays Public Ltd has 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 2,330 shares. Amer Century Incorporated stated it has 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Fmr stated it has 0.03% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH).

Since September 6, 2017, it had 0 insider buys, and 1 sale for $451,350 activity. Shafer Bradford J also sold $451,350 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) on Wednesday, September 6.